Lonza has signed an agreement to acquire Genentech's biologics manufacturing site in Vacaville, California (USA) from Roche. The Swiss pharmaceutical company announced...

Epsilogen and Lonza have successfully completed the manufacturing of a potential cancer treatment. The complex process, which took less than ten months, was carried out...

At its Capital Markets Day in Visp, Switzerland, Lonza shared a detailed update on its strategic priorities and provided new Mid-Term Guidance for 2024 to 2028.

When developing an inhaled powder formulation, the drug particles’ properties are critical to successful delivery to the deep lung. The aerodynamic diameter is the key...

Swiss contract development and manufacturing organization (CDMO) Lonza is extending a long-term collaboration with an unnamed major global biopharmaceutical partner...

Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September.

Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.

Lonza has signed a definitive agreement to divest its Specialty Ingredients business to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion.

For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.